JPMorgan lowered the firm’s price target on GSK (GSK) to 1,400 GBp from 1,460 GBp and keeps an Underweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK’s New Phase 3 Study: A Potential Game-Changer in Lung Cancer Treatment
- GSK’s Bepirovirsen Study: A Potential Game-Changer for Hepatitis B Treatment?
- GSK’s Mepolizumab Study: A Potential Game-Changer in Severe Asthma Treatment
- GSK’s Q2 2025 Earnings Call: Strong Growth Amid Challenges
- Is MRNA Stock (MRNA) a Buy Ahead of Q2 Earnings?